Pharmacy Medical Policy Updates

The following Pharmacy Medical Policy programs were updated Sept. 1, 2025:

Effective Oct. 1, 2025:

• Ctexli
• Elmiron
• GLP-1 Agonists
• IL-1 Inhibitor
• Phosphate Binder
• PPI
• Resmetirom
• SA Oncology
• Sensipar PA
• Topriamate ER
• Urinary Incontinence QL
• Vanrafia
• Weight Management
• Xdemvy
• Xphosah
• Yorvipath

Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.

To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website.

If you have any questions, please contact your BCBSKS provider relations representative.